Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-7547
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US ; volume:16 ; number:1 ; day:30 ; month:1 ; year:2018 ; pages:1-8 ; date:12.2018
Cost effectiveness and resource allocation ; 16, Heft 1 (30.1.2018), 1-8, 12.2018
- Schlagwort
-
Atemwegskrankheit
Atemnot
- Beteiligte Personen und Organisationen
-
Zafari, Zafar
Sadatsafavi, Mohsen
Mark FitzGerald, J.
SpringerLink (Online service)
- DOI
-
10.1186/s12962-018-0089-8
- URN
-
urn:nbn:de:1111-201803261860
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:46 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Zafari, Zafar
- Sadatsafavi, Mohsen
- Mark FitzGerald, J.
- SpringerLink (Online service)
Ähnliche Objekte (12)
4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry
Real-world effectiveness of omalizumab for severe allergic asthma treatment in Colombia
Severe asthma and the omalizumab option
Poster 1012: Safety and efficacy of omalizumab in 10 children with asthma and other allergic comorbidities
Follicular T Helper and Breg Cell Balance in Severe Allergic Asthma Before and After Omalizumab Therapy
Omalizumab in the treatment of severe allergic (IgE-mediated) asthma: an update on recent developments
Cost-effectiveness analysis of dupilumab among patients with uncontrolled severe asthma using LIBERTY ASTHMA QUEST Korean data
Omalizumab in children with severe allergic disease: a case series
Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: the real life observational PROXIMA study
Population-Based Pharmacodynamic Modeling of Omalizumab in Pediatric Patients with Moderate to Severe Persistent Inadequately Controlled Allergic Asthma
Effectiveness of the Polish program for the treatment of severe allergic asthma with omalizumab: a single-center experience
Poster 1014: Omalizumab efficiency in patients with allergic rhinitis and chronic sinusitis
4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry
Real-world effectiveness of omalizumab for severe allergic asthma treatment in Colombia
Severe asthma and the omalizumab option
Poster 1012: Safety and efficacy of omalizumab in 10 children with asthma and other allergic comorbidities
Follicular T Helper and Breg Cell Balance in Severe Allergic Asthma Before and After Omalizumab Therapy
Omalizumab in the treatment of severe allergic (IgE-mediated) asthma: an update on recent developments
Cost-effectiveness analysis of dupilumab among patients with uncontrolled severe asthma using LIBERTY ASTHMA QUEST Korean data
Omalizumab in children with severe allergic disease: a case series
Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: the real life observational PROXIMA study
Population-Based Pharmacodynamic Modeling of Omalizumab in Pediatric Patients with Moderate to Severe Persistent Inadequately Controlled Allergic Asthma
Effectiveness of the Polish program for the treatment of severe allergic asthma with omalizumab: a single-center experience
Poster 1014: Omalizumab efficiency in patients with allergic rhinitis and chronic sinusitis
4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry
Real-world effectiveness of omalizumab for severe allergic asthma treatment in Colombia
Severe asthma and the omalizumab option
Poster 1012: Safety and efficacy of omalizumab in 10 children with asthma and other allergic comorbidities
Follicular T Helper and Breg Cell Balance in Severe Allergic Asthma Before and After Omalizumab Therapy
Omalizumab in the treatment of severe allergic (IgE-mediated) asthma: an update on recent developments
Cost-effectiveness analysis of dupilumab among patients with uncontrolled severe asthma using LIBERTY ASTHMA QUEST Korean data
Omalizumab in children with severe allergic disease: a case series
Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: the real life observational PROXIMA study
Population-Based Pharmacodynamic Modeling of Omalizumab in Pediatric Patients with Moderate to Severe Persistent Inadequately Controlled Allergic Asthma
Effectiveness of the Polish program for the treatment of severe allergic asthma with omalizumab: a single-center experience